Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 2Phase 1 2Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian High Grade Serous Adenocarcinoma 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 901Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 433Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Atovaquone × Clear all
NCT05998135 2025-09-11

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

Emory University

Phase 2 Recruiting
28 enrolled
Gynecologic

Ovarian High Grade Serous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡